Spero Therapeutics (SPRO) Free Cash Flow (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Free Cash Flow data on file, last reported at $15.9 million in Q1 2026.

• Quarterly Free Cash Flow rose 496.4% year-over-year to $15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 121.69% YoY) and the FY2025 annual result came in at -$12.6 million, up 46.15% from the prior year.
• Free Cash Flow improved to $15.9 million in Q1 2026, from -$8.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $44.5 million in Q4 2022 to a low of -$28.2 million in Q1 2022.
• A 5-year average of -$3.6 million and a median of -$8.4 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 1763.01% — and 2025, when it tumbled 167.4%.
• Tracing SPRO's Free Cash Flow over 5 years: stood at $44.5 million in 2022, then sank by 139.33% to -$17.5 million in 2023, then plunged by 33.77% to -$23.4 million in 2024, then surged by 64.31% to -$8.4 million in 2025, then soared by 289.97% to $15.9 million in 2026.
• The last three Free Cash Flow figures came in at $15.9 million (Q1 2026), -$8.4 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.